Navigation Links
New Drug ALT-711 decreases blood vessel stiffness

A novel drug that breaks down collagen bonds in the body's blood vessels significantly decreases the stiffness of vessels in older people, according to a study conducted by National Institute on Aging (NIA) scientists and others. The finding suggests the medication could be a new treatment for high blood pressure, heart failure, and certain complications of diabetes. The drug, ALT-711, snips bonds or crosslinks created in the arteries and other tissues when glucose attaches to the protein collagen. //

Crosslinks are cable-like structures that inhibit the natural flexibility of collagen strands. They tend to proliferate with age. Crosslinks appear to toughen tissues and may contribute to some of the deterioration associated with aging and diabetes, such as elevated systolic blood pressure, stiff arteries, and impaired kidney function.

The ability to reduce vascular stiffness could have a major influence on reducing deaths from heart disease. For the current study, investigators at nine U.S. clinical centers recruited 93 people over the age of 50 who showed evidence of vascular stiffening, including high systolic blood pressure and pulse pressure of at least 60 mm Hg.

The participants were randomly divided into two groups-those who received daily doses of ALT-711 and those who were given a placebo daily. After 56 days, arterial pulse pressure - the difference between systolic and diastolic blood pressures - was significantly reduced among those taking the drug compared to the placebo group.


'"/>




Page: 1

Related medicine news :

1. Headache decreases appetite
2. Contraceptives decreases Libido
3. Alcohol decreases risk of dementia
4. Cooling decreases heart attack effects
5. Vitamin E decreases high blood pressure in kidney failure
6. Light therapy decreases depression during pregnancy
7. Perceived stress decreases vaccine response
8. Infant receives first bloodless liver transplant
9. Spouses and other partners lower blood pressure says new research
10. H2O - a cure for low blood pressure
11. Uncontrolled blood pressure
Post Your Comments:
(Date:5/16/2008)...ntry needs is more unemployed politicians - and ec...tCall/ -- Although nearly all,voters place health ...ist,a looming federal budgetary crunch means none...urrent presidential candidates is likely to become...y Leader Bill Frist., Jousting with Princeton Uni...
(Date:5/16/2008)...year-old Chinese students learn the lesson of help...uan earthquake, NANJING, China, May 16 /PRNewswir...earthquake, even the youngest members of China are...ef efforts. All around the,country, schools are ru...Led by the school,s principal, Ms. Zhang Lijun, th...
(Date:5/16/2008)...May 16 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Na...he treatment of cardiac,arrhythmias, announced tod...oCor common stock filed a complaint in the Superio...Diego, naming as defendants each member of the,Boa...entific Corporation.,The complaint is styled Secon...
(Date:5/16/2008)...Y., May 16 /PRNewswire-USNewswire/ -- Karin Weisbu...he nonprofit publisher of,Consumer Reports magazin...of the Year at CU,s Yonkers headquarters today., ...d. She bundles up in,the winter and rides in shirt...akes her along Quaker Ridge in New Rochelle, down ...
Breaking Medicine News(10 mins):Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Chinese Preschoolers Participate in Fund Drive to Help the Victims of Sichuan Quake 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 2Health News:Westchester Cycle Club Awards Consumers Union Staffer Karin Weisburgh Commuter of the Year 3
...Health Experts have called for a ban on junk foods...ublic institutions to help reduce the rate of diab...test-growing childhood obesity rate, and obesity i.... In an article published in this week's Medical ...
...A new study carried out by a team lead by Salim Yu...nada found that all forms of tobacco use increases... in the Lancet Medical journal found that Tobacco ...ewed first hand or second hand, increases the risk...
...Women are turning away from entering male-dominate...o their concerns about balancing career and family...al, University of Minnesota, University of Michiga... a 1990 study looked at 137 female high school sen...
...Bird flu outbreaks have been detected in two more ...ham. According to officials, around 3000 ducks hav...o more outbreaks of bird flu, but it has not infec..., the director of animal health at the agriculture...
Other Medicine News:
(Date:5/16/2008)...ghlights Include:, -- Results demonstrating that ...ically meaningful extension of progression-free su... to attack both the inside and,outside of the HER2..., -- Data demonstrating activity of TYKERB alone ... lines of trastuzumab and chemotherapy, LONDON an...
(Date:5/16/2008)...gle Molecule with Dual Mechanism May Offer Novel A... Management, NEW ORLEANS, May 16 /PRNewswire-Firs...r in the discovery and development of novel small,...40, its first-in-class,Dual Acting Receptor Antago...d pressure reductions in a Phase 2a study in patie...
(Date:5/15/2008)...SEL, Switzerland, May 15 /- Patients ...,s most common cancers, can expect,further treatme...eptin(R),(trastuzumab) following new data that is ...inical Oncology (ASCO) annual meeting in Chicago a...ll attend the meeting which,is the premier event f...
(Date:5/15/2008)...e II Data Presented at ASCO Showed Acceptable Tole...f Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N.J.,...herapeutic agent eribulin mesylate (E7389) demonst...of women with locally advanced or metastatic,breas...hase II clinical,trial. The study also suggests th...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Briefing on a new Web resource to address global drinking water crisis 573 1Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids 569 1Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids 569 2Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids 569 3Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids 569 4Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic Debilitating and Life Threatening Illness Access Quality Healt 565 1Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic Debilitating and Life Threatening Illness Access Quality Healt 565 2Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic Debilitating and Life Threatening Illness Access Quality Healt 565 3Pressure BioSciences Inc Announces CE Mark Approval and Compliance with the IEC 61010 1 Standard for a Second PCT based Instrument the Barocycler N 386 1Pressure BioSciences Inc Announces CE Mark Approval and Compliance with the IEC 61010 1 Standard for a Second PCT based Instrument the Barocycler N 386 2Pressure BioSciences Inc Announces CE Mark Approval and Compliance with the IEC 61010 1 Standard for a Second PCT based Instrument the Barocycler N 386 3Pressure BioSciences Inc Announces CE Mark Approval and Compliance with the IEC 61010 1 Standard for a Second PCT based Instrument the Barocycler N 386 4
...stration of rubella IgG antibody in women prior to... from possible rubella viral infection during preg...dren has greatly reduced the incidence of rubella ...nitoring of immune status, especially for women of...
...stration of rubella IgG antibody in women prior to... from possible rubella viral infection during preg...dren has greatly reduced the incidence of rubella ...nitoring of immune status, especially for women of...
... Bard BrachyStar® Needle is designed to help y...inically effective brachytherapy procedure. All ne...featuring ultra-sharp tips and polished surfaces f...dle configurations and sizes assures an ideal matc...
The autoclavable, aluminum needle box is designed to store loaded needles and help protect personnel from exposure. Each shield consists of an aluminum box with faceplate to match the grid pattern th
Medicine Products: